恢复期血浆治疗与COVID-19患者临床结局的关联:系统综述与Meta分析
结果显示,恢复期血浆与全因死亡率下降无显著关联,对其他临床结局亦无获益,证据确定性为低至中等。
要点
- 恢复期血浆未显著降低全因死亡率(RR 0.93,95%CI 0.63-1.38),证据确定性低。
- 纳入所有10项随机试验后,全因死亡率RR为1.02(95%CI 0.92-1.12),证据确定性中等。
- 机械通气使用、住院时长等结局均无显著差异,证据确定性低。
核心结论
- 与安慰剂或标准治疗相比,恢复期血浆未显著降低全因死亡率,对其他临床结局亦无获益。
- 全因死亡率的证据确定性为低至中等,其他结局的证据确定性为低。
研究设计与样本
- 系统综述与Meta分析,纳入同行评议的随机临床试验(RCT)及公开的预印本或新闻稿RCT数据。
- 检索PubMed、Cochrane COVID-19试验注册库和Living Overview of Evidence平台,截至2021年1月29日。
主要发现
- 4项同行评议RCT中,全因死亡率的汇总风险比(RR)为0.93(95%CI 0.63-1.38),绝对风险差为-1.21%(95%CI -5.29%至2.88%)。
- 所有10项RCT中,全因死亡率的汇总RR为1.02(95%CI 0.92-1.12)。
- 同行评议RCT中,住院时长的汇总风险比为1.17(95%CI 0.07-20.34)。
- 同行评议RCT中,机械通气使用的汇总RR为0.76(95%CI 0.20-2.87),绝对风险差为-2.56%(95%CI -13.16%至8.05%)。
- 临床改善、临床恶化和严重不良事件的有限数据显示无显著差异。
关键数值与推荐
- 全因死亡率(4项同行评议RCT):RR 0.93(95%CI 0.63-1.38),绝对风险差-1.21%(95%CI -5.29%至2.88%),证据确定性低(因不精确性)。
- 全因死亡率(所有10项RCT):RR 1.02(95%CI 0.92-1.12),证据确定性中等(因纳入未发表数据)。
- 住院时长(同行评议RCT):汇总风险比1.17(95%CI 0.07-20.34),证据确定性低。
- 机械通气使用(同行评议RCT):RR 0.76(95%CI 0.20-2.87),绝对风险差-2.56%(95%CI -13.16%至8.05%),证据确定性低。
临床怎么用
- 不推荐常规使用恢复期血浆治疗COVID-19以降低死亡率或改善其他临床结局。
- 临床决策应结合低至中等确定性的证据,并考虑其他有效治疗措施。
局限性
- 部分RCT数据来自未发表的预印本或新闻稿,可能引入偏倚。
- 主要分析仅纳入4项同行评议RCT,样本量有限(1060例),证据不精确。
- 临床改善、临床恶化和严重不良事件的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Convalescent plasma is a proposed treatment for COVID-19. OBJECTIVE: To assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care in peer-reviewed and preprint publications or press releases of randomized clinical trials (RCTs). DATA SOURCES: PubMed, the Cochrane COVID-19 trial registry, and the Living Overview of Evidence platform were searched until January 29, 2021. STUDY SELECTION: The RCTs selected compared any type of convalescent plasma vs placebo or standard of care for patients with confirmed or suspected COVID-19 in any treatment setting. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data on relevant clinical outcomes, trial characteristics, and patient characteristics and used the Cochrane Risk of Bias Assessment Tool. The primary analysis included peer-reviewed publications of RCTs only, whereas the secondary analysis included all publicly available RCT data (peer-reviewed publications, preprints, and press releases). Inverse variance-weighted meta-analyses were conducted to summarize the treatment effects. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation. MAIN OUTCOMES AND MEASURES: All-cause mortality, length of hospital stay, clinical improvement, clinical deterioration, mechanical ventilation use, and serious adverse events. RESULTS: A total of 1060 patients from 4 peer-reviewed RCTs and 10 722 patients from 6 other publicly available RCTs were included. The summary risk ratio (RR) for all-cause mortality with convalescent plasma in the 4 peer-reviewed RCTs was 0.93 (95% CI, 0.63 to 1.38), the absolute risk difference was -1.21% (95% CI, -5.29% to 2.88%), and there was low certainty of the evidence due to imprecision. Across all 10 RCTs, the summary RR was 1.02 (95% CI, 0.92 to 1.12) and there was moderate certainty of the evidence due to inclusion of unpublished data. Among the peer-reviewed RCTs, the summary hazard ratio was 1.17 (95% CI, 0.07 to 20.34) for length of hospital stay, the summary RR was 0.76 (95% CI, 0.20 to 2.87) for mechanical ventilation use (the absolute risk difference for mechanical ventilation use was -2.56% [95% CI, -13.16% to 8.05%]), and there was low certainty of the evidence due to imprecision for both outcomes. Limited data on clinical improvement, clinical deterioration, and serious adverse events showed no significant differences. CONCLUSIONS AND RELEVANCE: Treatment with convalescent plasma compared with placebo or standard of care was not significantly associated with a decrease in all-cause mortality or with any benefit for other clinical outcomes. The certainty of the evidence was low to moderate for all-cause mortality and low for other outcomes.
引用
- Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021. PMID: 33635310. doi:10.1001/jama.2021.2747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。